Brokerages forecast that Inovio Pharmaceuticals, Inc. (NASDAQ:INO – Get Rating) will announce earnings of ($0.30) per share for the current quarter, according to Zacks. Three analysts have issued estimates for Inovio Pharmaceuticals’ earnings, with estimates ranging from ($0.38) to ($0.23). Inovio Pharmaceuticals posted earnings per share of ($0.39) in the same quarter last year, which would suggest a positive year over year growth rate of 23.1%. The company is expected to announce its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that Inovio Pharmaceuticals will report full year earnings of ($1.22) per share for the current fiscal year, with EPS estimates ranging from ($1.60) to ($0.85). For the next year, analysts expect that the firm will report earnings of ($0.88) per share, with EPS estimates ranging from ($1.50) to ($0.63). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Inovio Pharmaceuticals.
Inovio Pharmaceuticals (NASDAQ:INO – Get Rating) last released its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.02). The firm had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.66 million. Inovio Pharmaceuticals had a negative return on equity of 76.48% and a negative net margin of 20,479.29%. Inovio Pharmaceuticals’s revenue was down 46.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.27) earnings per share.
Several hedge funds and other institutional investors have recently made changes to their positions in INO. Running Point Capital Advisors LLC acquired a new stake in shares of Inovio Pharmaceuticals during the 1st quarter valued at $36,000. Smith Anglin Financial LLC bought a new position in Inovio Pharmaceuticals during the 1st quarter worth $36,000. Covestor Ltd bought a new position in shares of Inovio Pharmaceuticals in the 4th quarter worth about $42,000. CIBC Asset Management Inc bought a new position in shares of Inovio Pharmaceuticals in the 4th quarter worth about $51,000. Finally, RFG Advisory LLC bought a new stake in Inovio Pharmaceuticals in the 4th quarter valued at about $52,000. Institutional investors own 43.28% of the company’s stock.
NASDAQ:INO opened at $1.84 on Thursday. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 0.05. Inovio Pharmaceuticals has a 1-year low of $1.60 and a 1-year high of $10.33. The firm has a market capitalization of $421.44 million, a price-to-earnings ratio of -1.19 and a beta of 0.80. The stock has a fifty day simple moving average of $3.09 and a 200 day simple moving average of $4.43.
Inovio Pharmaceuticals Company Profile (Get Rating)
Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
- Get a free copy of the StockNews.com research report on Inovio Pharmaceuticals (INO)
- Simply Good Foods Stock is Simply Looking Good Down Here
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
- Analog Devices Is Ready To Scale New Highs Despite Tech Wreck
- Dynatrace: Fundamentals are Positive While Being Punished
- Now’s The Time To Buy Disney (NYSE: DIS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.